)
)
Modus Therapeutics Investor Relations Material
Latest events
Q3 2024
Modus Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Modus Therapeutics Holding
Access all reports
Modus Therapeutics AB is a healthcare company engaged in the development of drugs for rare diseases. Its product Slevaoxin, is focused on alleviating the elevated levels of neutrophil extracellular traps, which could reduce the widespread damage to organs and tissues, and frequently leads to life-threatening organ failure and death. It also develops MPC-06-ID, a drug candidate to address infantile onset Idiopathic nephrotic syndrome in children below the age of 2.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
MODTX
Country
🇸🇪 Sweden